AMPRION


Associated tags: CSF, Amprion, Synuclein, Disease, Myenteric plexus, FDA, Alzheimer's disease, Parkinson's disease, Amprion

Locations: TEXAS, CANADA, AUSTRALIA, HONG KONG, NORTH AMERICA, INDIA, CHINA, UNITED STATES, BRAZIL, MEXICO, KOREA, SINGAPORE, ISRAEL, JAPAN, UK, EUROPA, DEUTSCHLAND, GERMANY, NORTH SEA, DEUTSCHLAND

EQS-News: Amprion accelerates grid expansion and invests more than ever before

Retrieved on: 
Friday, May 3, 2024

Transmission system operator Amprion is stepping up the pace of grid expansion and continues to grow.

Key Points: 
  • Transmission system operator Amprion is stepping up the pace of grid expansion and continues to grow.
  • By 2028 Amprion plans to invest around €27.5 billion in the expansion and upgrading of the transmission grid.
  • “The statutory measures introduced to accelerate grid expansion are having an impact.
  • Amprion has tripled its investments in grid expansion since 2021.

EQS-News: Fitch Ratings affirms “BBB+” rating with stable outlook for Amprion

Retrieved on: 
Friday, May 3, 2024

The international rating agency Fitch Ratings has awarded the transmission system operator Amprion GmbH ("Amprion") again a Long-Term Issuer Default Rating “BBB+” with a stable outlook as part of its annual review.

Key Points: 
  • The international rating agency Fitch Ratings has awarded the transmission system operator Amprion GmbH ("Amprion") again a Long-Term Issuer Default Rating “BBB+” with a stable outlook as part of its annual review.
  • Peter Rüth, Chief Financial Officer of Amprion, comments: "Our central role in enabling the energy transition and the associated grid expansion requires highest efforts to achieve the climate targets in Germany.
  • In this challenging environment we see this affirmation of our solid investment-grade rating 'BBB+’ by Fitch also as an appreciation of our stable business model and our reliable, sound financial policy."
  • Amprion plans to invest around € 27.5 billion in the expansion and upgrade of the transmission grid between the years 2024 to 2028.

EQS-News: Moody‘s affirms 'Baa1' rating with stable outlook for Amprion

Retrieved on: 
Wednesday, April 10, 2024

As part of its annual review, the transmission system operator Amprion GmbH ("Amprion") has again received a "Baa1" rating with stable outlook from the international rating agency Moody's Ratings.

Key Points: 
  • As part of its annual review, the transmission system operator Amprion GmbH ("Amprion") has again received a "Baa1" rating with stable outlook from the international rating agency Moody's Ratings.
  • In addition to this long-term rating, Moody's has also affirmed the "Prime-2" short-term and Commercial Paper ratings.
  • The confirmation of our solid investment-grade rating 'Baa1' by Moody's reflects our stable business model and our reliable financial policy."
  • The press release on the current rating is available on Moody’s Ratings homepage.

EQS-News: Amprion GmbH: Invitation to the 2023 annual results conference call for investors and analysts

Retrieved on: 
Wednesday, April 10, 2024

Amprion GmbH will publish its annual report for the financial year 2023 on Thursday, 11th April 2024.

Key Points: 
  • Amprion GmbH will publish its annual report for the financial year 2023 on Thursday, 11th April 2024.
  • On this occasion we cordially invite you to our:
    Peter Rüth, Chief Financial Officer of Amprion GmbH, will present the annual results for the financial year 2023 and will provide further insights into the business development.
  • The conference call will be held in English.
  • A recording of the call will be made available after the event on our corporate website.

EQS-News: Science Based Target initiative confirms Amprion's CO2 reduction targets

Retrieved on: 
Saturday, January 13, 2024

The CO2 reduction targets of the transmission system operator Amprion are in line with the Paris Climate Agreement.

Key Points: 
  • The CO2 reduction targets of the transmission system operator Amprion are in line with the Paris Climate Agreement.
  • This is the result of the scientific review of the reduction targets for Scopes 1 to 3 by the Science Based Target initiative (SBTi).
  • SBTi confirmed that Amprion's emission targets follow a reduction path in line with the goals of the Paris Climate Agreement.
  • Receiving this seal of approval from SBTi for our CO2 reduction targets is a further confirmation for us.